Background: Balloon aortic valvuloplasty (BAV) is a palliative treatment for severe aortic stenosis (AS) that is increasingly performed as a bridge to transcatheter aortic valve replacement. We investigated the independent predictors of vascular complications in AS patients who underwent BAV. Methods: We performed a retrospective review of consecutive patients who undergoing non-emergent, retrograde BAV at two high-volume US centers. We analyzed baseline and procedural characteristics as well as in-hospital outcomes according to the presence or absence of vascular complications, as classified by the Vascular Academic Research Consortium (VARC). Net adverse clinical events (NACE) were defined as composite of mortality, myocardial infarction, stroke and major bleeding. Results: Among 428 BAV patients, the average age was 83 Ϯ 9 years and 30 (7.0%) had vascular complications. Patients with vs. without vascular complications had higher rates of myocardial infarction (13.3% vs. 2.5%; pϭ0.001), stroke (6.7% vs. .03%; pϭϽ0.001), and NACE (33.3% vs. 9.8%; pϭϽ0.001). Multivariable adjusted predictors of vascular complications are shown in the Figure. Conclusions: In this large registry of BAV patients, pre-closure failure, thrombocytopenia and concurrent PCI were associated withincreased risk of vascular complications in patients undergoing BAV.
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TAVR-3 year results of transapical versus transfemoral approach in a real world population of 1000 patients with severe aortic stenosis Background: Transcatheter aortic valve replacement (TAVR) is the method of choice in inoperable patients with severe aortic stenosis and is gaining increasing importance in high risk patients and intermediate risk patients with additional critical comorbidities or frailty. Two methods of access were used, transfemoral (TF) or transapical (TA), and baseline characteristics, clinical outcomes and mortality to three years were evaluated in both groups. Patient selection for TA or TF was made after consensus between interdisciplinary heart team members. All procedures were performed in a hybrid OR by a dedicated TAVR team. Methods: Group I: TA in 413 patients (SAPIEN THV: 402, Symetis Acurate: 11), Group II: TF in 587 patients (SAPIEN THV: 399, CoreValve: 188); from 5/08 to 04/12 in a single center heart team. Results: The mean age in TA group was 81.0 years and in TF 81.6 years, pϭ0.3. The TA group had more patients with peripheral artery disease (22.0% vs 10.9%), coronary artery disease (64.4% vs 58.3%), carotid stenosis (23.2% vs 15. 7%), redo-operation (25.7% vs 14.8%) and neurological dysfunction (14.8% vs 10.4%) than in TF (all pϽ0.05). In TF more patients were seen with pulmonary hypertension (22.0% vs 15.5%, pϽ0.05). The mean EuroSCORE I in TA was 24.2% and in TF 22.3% (pϭ0.007). Mortality at three years in TA was 33.7% and 27.3% in TF. Conclusions: With a dedicated, experienced heart team in a hybrid OR, patients with severe aortic stenosis can be treated with similar rates of mortality regardless of approach and despite the fact that one group has significantly more comorbidities. (28%). Reasons to decline TAVI in favour of AVR/MT were patient's preference (29%) and peripheral vascular disease (15%; Figure 1 ). The logistic EuroSCORE was significantly higher in patients who underwent TAVI and MT in comparison to those undergoing AVR (19 vs. 10%, pϭ0.007). At 30 days, all-cause mortality and the combined safety endpoint was, respectively, 9 and 24% after TAVI and 8 and 25% after AVR. All-cause mortality was significantly lower in the TAVI group compared to the MT group at 6 months, 1 year and 2 years (12% vs. 22%, 21% vs. 33% and 31% vs. 55%, respectively, pϽ0.001). Multivariable analysis revealed that blood transfusion (HR: 1.19; 95% CI: 1.05-1.33), pre-existing renal failure (HR: 1.18; 95% CI: 1.06-1.33) and STS score (HR: 1.06; 95% CI: 1.02-1.10) were independent predictors of mortality at a median of 10 (IQR: 3-23) months after TAVI.
Conclusions:
Approximately two-thirds of the patients referred for TAVI receive this treatment with gratifying short-and long-term survival. Another 7% underwent AVR. Prognosis is poor in patients who do not receive valve replacement therapy. Background: Aortic stenosis is the most common valvulopathy in industrialized countries which is treated with trancatheter aortic valve implantation (TAVI) when patients are inoperable or high risk. Nevertheless, female sex constitutes an unfavorable predictive factor for the outcome of transcatheter interventions for heart diseases. In this study we will evaluate baseline clinical characteristics, echocardiography parameters as well as electrocardiographic changes before and after TAVI. Methods: Consecutive patients who underwent TAVI years were evaluated from an existed database. Baseline characteristics were collected before TAVI while echocardiograms and ECGs were recorded before TAVI and daily for 5 days after the procedure. We separated patients in two groups according to gender. 
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Sex-related clinical characteristics and outcome before and after trancatheter aortic valve implantation
